Simian varicella virus (SVV) infection in primates closely resembles varicella-zoster virus (VZV) infection in humans. SVV ORF 63 has 51.6% homology at the amino acid level to VZV ORF 63. We cloned SVV ORFs 63 and 62, transcribed and translated in vitro, and immunoprecipitated the expected proteins with rabbit polyclonal antibodies. Immunoprecipitation analysis revealed that SVV ORF 63 is expressed as a 43-kDa phosphorylated protein in virus-infected cells. In both neuronal and non-neuronal cells, SVV ORF 62 protein alone upregulated the SVV 21 promoter, while SVV ORF 63 protein alone did not have any effect. SVV ORF 62-mediated transactivation of the SVV ORF 21 promoter was upregulated in neuronal cells, but downregulated in non-neuronal cells, by SVV ORF 63 protein. This is the first study in which a varicella protein (ORF 63) expressed during latency has been shown to have a differential effect on a promoter that is also active during latency, in neuronal as compared to non-neuronal cells.
Introduction
Simian varicella virus (SVV) infection of primates shares many clinical and immunovirological features with human varicella zoster virus (VZV). At the molecular level, analysis of the complete nucleotide sequence of 124,139 base pairs of the SVV genome (Gray et al., 2001) has revealed 69 potential open reading frames (ORFs), several of which are highly homologous to VZV ORFs. During latency in human ganglia, no less than five VZV genes (ORFs 21, 29, 62, 63, and 66) are transcribed. SVV and VZV ORFs 62 and 63 share 58% and 52% amino acid identity, respectively (Gray et al., 1995) . While the regulatory function of VZV ORF 63 is controversial (Jackers et al., 1992; Kost et al., 1995 , Bontems et al., 2002 , VZV ORF 62 has been shown to transactivate all putative kinetic classes of VZV genes (Baudoux et al., 1995; Perera et al., 1992) . It is not known whether SVV ORF 62 and 63 regulate other SVV genes.
We have identified the SVV ORF 21 promoter and shown that SVV infection is essential for its activity (Mahalingam et al., 2000) . Herein, we questioned whether SVV ORF 62 and 63 activate the SVV ORF 21 promoter and if SVV ORF 63 influences transactivation by SVV ORF 62. Because SVV, like VZV, is latent in ganglionic neurons (Kennedy et al., 2004) , we also studied the effect of SVV 63 protein on SVV ORF 62 transactivation of the SVV 21 promoter in both neuronal and non-neuronal cells.
Results
SVV and VZV ORF 63 share amino acid homology SVV and VZV ORF 63 are predicted to encode 29.3-and 30.5-kDa polypeptides, respectively (Davison and Scott, 1986;  Gray et al., 2001) , and ORF 63 of SVV and VZV share 51.6% amino acid homology (Gray et al., 1995) . Comparison of the two amino acid sequences ( Fig. 1) revealed several interesting features: amino acids 26-157 in VZV ORF 63, referred to as region 2, shares 67% amino acid identity with the region 2 segment of SVV ORF 63. Region 2 is highly conserved between different alpha herpesviruses and is predicted to mediate binding to homologs of VZV ORF 62 (Baiker et al., 2004) . Specifically, amino acid residues R59 and L60 of VZV ORF 63 are important for VZV ORF 62 binding (Baiker et al., 2004) . These two amino acids are the same in the VZV and SVV 63 ORFs. Residues S165, S173, and S185 are sites of phosphorylation by cellular kinases (Bontems et al., 2002; Stevenson et al., 1996) , and two of these serine residues (S165 and S173) are conserved in SVV ORF 63. The nuclear localization signals are in the carboxyl terminus (amino acids 142 -210) of VZV ORF 63 (Stevenson et al., 1996) , a region of SVV ORF 63 that shares 48% amino acid identity with its VZV counterpart. Of two nuclear localization signals (KRRR; 260 -263 and KRPQ; 226-229) (Baiker et al., 2004; Stevenson et al., 1996) , one (KRPR, (225) (226) (227) (228) is shared by SVV ORF 63.
Cloning of SVV ORFs 62 and 63 into an expression vector
Based on the published sequence of the inverted repeat regions of the SVV genome (Gray et al., 2001) , SVV ORFs 62 and 63 were cloned into the expression vector pCI-neo, downstream from the CMV promoter ( Fig. 2) .
Expression in vitro and immunoprecipitation of SVV ORFs 62 and 63
Size and specificity of the polypeptide encoded by the recombinant clones containing SVV ORFs 62 or 63 were determined using in vitro translation (ivt) of RNAs transcribed from linearized recombinant plasmids in the rabbit reticulocyte system. SDS-PAGE revealed a major band at the 165-kDa position for SVV ORF 62. The protein was absent when no RNA was used for translation. The 165-kDa protein was immunoprecipitated with rabbit anti-SVV antiserum, but not with preimmune serum or when no RNA was used in the ivt reaction ( Fig. 3A) . Thus, the recombinant clone encoding SVV 62 ORF probably contains the complete polypeptide. The translated SVV ORF 62 was much larger than the size predicted (136.8 kDa) based on the nucleotide sequence (Gray et al., 2001) , consistent with previous observations (Forghani et al., 1990) .
SDS-PAGE analysis of the polypeptide encoded by SVV ORF 63 and transcribed and translated using the rabbit reticulocyte system from a linearized recombinant plasmid containing SVV ORF 63 DNA revealed a major band at 41 kDa (Fig. 3B ). The protein was absent when RNA was omitted from the translation reaction. The 41-kDa product did not react with rabbit anti-SVV antiserum (data not shown). Based on the amino acid homology of the SVV and VZV ORF 63, we used rabbit anti-VZV 63 serum, which has been used to identify VZV gene 63 protein in human ganglia (Mahalingam et al., 1996) , for immunoprecipitation. A 41-kDa translation product was immunoprecipitated, while use of a rabbit preimmune serum or absence of RNA in the translation reaction revealed no such band (Fig. 3B ). The observed size of the SVV ORF 63 was much larger than the size predicted (29.3 kDa) by the nucleotide sequence (Gray et al., 2001) , as previously observed using VZV ORF 63 (Davison and Scott, 1986; Kinchington et al., 1995) . Two other polypeptides (30 -35 kDa) were also immunoprecipitated with rabbit-anti-VZV 63 antiserum. These could be degradation products since protein of similar sizes was also seen in the immunoprecipitation of ivt products in Fig. 3B . 
SVV ORF 63 is phosphorylated
Immunoprecipitation of [ 35 S]methionine-labeled uninfected (BSC-1) or SVV-infected (BSC-1 -SVV) cell lysates with rabbit preimmune serum or rabbit anti-VZV 63 antiserum followed by SDS-PAGE analysis revealed a 41-kDa 35 Slabeled band in SVV-infected cells, but not in uninfected cells (Fig. 4) . These results, together with the immunoprecipitation data in Fig. 3B , indicate that SVV ORF 63 encodes a 41-kDa protein.
Similar analyses of SVV-infected cell lysates labeled with [ 32 P]pyrophosphate detected a 43-kDa phosphorylated protein in virus-infected cells (Fig. 4 ), but not in uninfected cells (data not shown) immunoprecipitated with rabbit anti-VZV 63 antiserum. The difference in the size between the 35 S-labeled (41 kDa) and 32 P-labeled (43 kDa) SVV ORF 63 protein could reflect alterations in migration because of phosphorylation and the presence of multiple phosphorylation sites as previously described for VZV gene 63 protein (Debrus et al., 1995) . Thus, in Fig. 4 , Fig. 3 . In vitro expression and immunoprecipitation of SVV ORFs 62 (A) and 63 (B) proteins. Recombinant plasmids containing either SVV ORF 62 or 63 were linearized with NotI and used as templates for in vitro transcription. The RNAs were translated in vitro (ivt) in the presence of [ 35 S]methionine, and the radiolabeled products were immunoprecipitated with rabbit preimmune serum, rabbit anti-SVV antiserum, or rabbit polyclonal antibodies raised against VZV ORF 63. The ivt product and immunoprecipitates were analyzed by SDS-PAGE. Molecular mass markers and the apparent molecular size of the major polypeptides encoded by SVV ORFs 62 (165 kDa) and 63 (41 kDa) are indicated. Results from control experiments in which RNA was omitted in the ivt reaction are shown. phosphorylated 43 kDa is seen better than methioninelabeled 41 kDa.
SVV ORF 63 protein upregulates transactivation of the SVV ORF 21 promoter by SVV ORF 62 in neuronal, but not in non-neuronal cells SVV ORF 62 transactivation of the SVV ORF 21 promoter and the effect of SVV ORF 63 on this transactivation were assessed in non-neuronal (Vero and MeWo) and neuronal (SK-SY-5Y) cells co-transfected with a mixture of recombinant plasmids (2000 ng) containing varying amounts of SVV ORFs 62 and 63 along with a plasmid containing the SVV ORF 21 promoter that drives the luciferase reporter gene. All transfection results were normalized to Renilla luciferase which was used as an internal control. Therefore, the observations were independent of the differences in transfection efficiencies between cell lines. In both non-neuronal cell lines, SVV ORF 62 activated the SVV ORF 21 promoter and SVV ORF 63 by itself did not activate the SVV 21 promoter but did suppress the ability of SVV ORF 62 to transactivate the SVV ORF 21 promoter ( Figs. 5A and B) ; suppression was¨30% in Vero cells and¨50% in MeWo cells. The influence of SVV ORF 63 on SVV ORF 62 activation in non-neuronal cells was evident with as little as 50 ng of plasmid containing SVV ORF 62 used in transfection. In contrast, SVV ORF 63 did not suppress activation of the SVV ORF 21 promoter by SVV ORF 62 in neuronal cells (Fig. 5C ).
Similar analyses were carried out using a constant amount (50 ng) of SVV ORF 62 plasmid DNA and varying amounts (0-1200 ng) of SVV ORF 63 in transfection of two different human neuronal cell lines (SH-SY-5Y and SKNMC) and nonneuronal cells. In non-neuronal cells transfected with 50 ng of SVV ORF 62 without SVV ORF 63, SVV ORF 21 promoter activity was increased 50-fold; with increasing concentrations of SVV ORF 63 (300 -1200 ng), activation decreased to 30fold (Fig. 6A) . In both neuronal cell lines, only 5-fold activation was observed when 50 ng of SVV ORF 62 was used alone in transfection without SVV ORF 63; with increasing concentrations of SVV ORF 63 (300 -1200 ng), activation rose to 20-fold in SH-SY-5Y cells and to 10-fold in Fig. 5 . Transactivation of the SVV ORF 21 promoter by SVV ORFs 62 and 63 in neuronal and non-neuronal cells in culture. Monolayers of monkey kidney (Vero) (A), human melanoma (MeWo) (B), or human neuroblastoma (SH-SY-5Y) (C) cells cultured in 12-well plates to 70% confluence were transfected with 800 ng of a plasmid containing firefly-luciferase driven by the SVV ORF 21 promoter, along with varying amounts of recombinant clones containing SVV ORF 62 or 63. The quantity (ng) of the SVV ORF 62-containing plasmid is shown on the x axis. For each time point, the total amount of DNA was brought to 2000 ng by addition of either vector DNA or SVV ORF 63containing plasmid. Cells were lysed 24 h after transfection and assayed for luciferase using the dual luciferase assay kit (Promega). Firefly-luciferase activities were normalized with Renilla luciferase activity, an internal control for transfection efficiency. Results are given as fold activation over the activity observed when SVV ORF 21 promoter was used without SVV gene 62 DNA. Values represent the mean (TSE) for 3 independent experiments. P < 0.001 when activation by SVV ORF 62 alone was compared to vector control. P < 0.01 when SVV ORF 62 and 63 was compared to SVV ORF 62 alone. SVV ORF 21 promoter is activated by SVV ORF 62 but not by SVV ORF 63. Downregulation of SVV ORF 62 transactivation of SVV ORF 21 promoter by SVV ORF 63 is observed in non-neuronal but not in neuronal cells. SKNMC cells (Figs. 6B and C) . Very similar results were obtained when the quantity of SVV ORF 62 was maintained at 200 ng with varying quantities of SVV ORF 63 (data not shown). Overall, increasing concentrations of SVV ORF 63 was accompanied by downregulated SVV ORF 62 activity in non-neuronal cells but upregulated activity in neuronal cells.
Discussion
ORF 63 appears to be the most prevalent transcript produced from the five known VZV ORFs that are expressed during latency in human ganglia (Cohrs et al., 2000) . Nevertheless, the exact role of varicella ORF 63 in latency and pathogenesis remains unknown. Both VZV and SVV become latent in ganglionic neurons. To determine whether varicella ORF 63 functions differently in neuronal cells compared to non-neuronal cells, we cloned SVV ORFs 62 and 63 into an expression vector, identified their cognate proteins in vitro ( Figs. 3 and 4) , and examined the influence of SVV ORF 63 protein on transactivation of the SVV 21 promoter by SVV ORF 62 in neuronal and non-neuronal cells. SVV ORF 62 protein by itself transactivated the SVV ORF 21 promoter 50-to 200-fold in non-neuronal cells compared to 10-to 70-fold in neuronal cells (Figs. 5 and 6) . These findings are consistent with an earlier study in which VZV ORF 62 transactivated the VZV ORF 28 promoter more in nonneuronal (Vero) cells than in cells (ND7) of neuronal origin (Bontems et al., 2002) . Comparison of the effect of the SVV ORF 63 protein on the transactivation function of SVV ORF 62 protein in non-neuronal and neuronal cells revealed a suppressive activity of SVV ORF 63 protein on SVV ORF 62 induction of the SVV ORF 21 promoter in non-neuronal cells. This downregulation was more extensive in melanoma cells than in Vero cells (Figs. 5A and B) . Interestingly, VZV ORF 63 was shown to upregulate transactivation of the VZV gI promoter by VZV ORF 62 in non-neuronal T cells (Lynch et al., 2002) .
In neuronal cells, SVV ORF 63 protein did not suppress SVV ORF 62 protein activation of the SVV ORF 21 promoter; in fact, the transactivation was slightly upregulated. Nevertheless, previous analysis of the effect of VZV gene 63 and VZV gene 62 proteins on a different promoter (VZV ORF 28) indicated downregulation in both non-neuronal and neuronal cells (Bontems et al., 2002) . Recently, it has been shown (Zuranski et al., 2005) that, in transfection experiments, the levels of varicella ORF 63 protein are equivalent in MeWo (non-neuronal) and SK-SY-5Y (neuronal) cells, although its influence on the transactivation of cellular promoters was celltype-specific.
Thus, the influence of varicella ORF 63 protein on ORF 62 function may be both cell-type-specific, as well as promoterspecific. Furthermore, there could be some differences between cells of neuronal origin and mature differentiated neurons in monkeys.
Overall, SVV ORF 63 protein appears to function differently in neuronal than in non-neuronal cells. Further analysis of varicella gene 63 -protein interaction with other viral and cellular genes may help to elucidate the mechanisms of varicella pathogenesis and latency.
Materials and methods

Cells and viruses
African green monkey kidney cells (Vero cells) were used to propagate SVV. Vero cell, human melanoma (MeWo) cells, and Monolayers of human melanoma (MeWo) (A) or human neuroblastoma cells (SH-SY-5Y or SKNMC) (B and C) cultured in 12-well plates to 70% confluence were transfected with 700 ng of a plasmid containing fireflyluciferase driven by the SVV ORF 21 promoter, or 50 ng of the plasmid containing SVV ORF 62, and varying amounts of recombinant clones containing SVV ORF 63. The quantity (ng) of SVV ORF 63-containing plasmid is shown on the x axis. For each time point, the total quantity of DNA was brought to 1950 ng by addition of either vector DNA pCI-neo. Cells were lysed 24 h after transfection and assayed for luciferase using the dual luciferase assay kit (Promega). Firefly-luciferase activities were normalized with Renilla luciferase activity, an internal control for transfection efficiency. Results are given as fold activation over the observed activity when SVV ORF 21 promoter was used without SVV gene 62 DNA. Values represent the mean (TSE) for 3 independent experiments. **P < 0.001 when compared to vector control. *P < 0.01 when compared to promoter + SVV ORF 62. Overall, the activity of SVV ORF 62 is downregulated by SVV ORF 63 in non-neuronal cells and upregulated in neurons. two lines of human neuroblastoma cells (SH-SY-5Y and SKNMC; American Type Culture Collection, Manassas, VA) were used for transfections. Veros as well as MeWos are permissive for SVV infection. SVV infection of SH-SY-5Y and SKNMC cells has not been tested.
Alignment of SVV and VZV ORF 63 sequences
Based on the published sequences of the SVV (Gray et al., 2001) and VZV (Davison and Scott, 1986 ) genomes, the predicted amino acid sequences for ORF 63 were aligned using Vector NTI Suite software (Invitrogen, Carlsbad, CA).
Cloning of SVV ORFs 62 and 63 into pCI-neo
A recombinant clone containing the SVV BamHI-D fragment in pGem7Z (Promega, Madison, WI) was digested with SnaBI and AspI, and the 4544-bp AspI-SnaBI and the 1350-bp SnaBI -BamHI fragments were isolated from agarose gels, treated with T7 DNA polymerase, and ligated to SmaIdigested and dephosphorylated pCI-neo (Clontech, Palo Alto, CA). The ligation products were used to transform Top10F Vcompetent cells (Invitrogen). Recombinant clones containing the desired inserts were identified by restriction analysis.
In vitro transcription and translation
Recombinant clones containing SVV ORF 62 or 63 were linearized by digestion with NotI and cleaned by phenol extraction and ethanol precipitation. Linearized DNA (1 Ag) was used in an in vitro transcription reaction with T7 RNA Polymerase (Life Technologies, Gaithersburg, MD) according to the manufacturer's instructions. In-vitro-transcribed RNA (3 Ag) was translated in the presence of [ 35 S]methionine using the nuclease-treated rabbit reticulocyte lysate system (Promega) as per the manufacturer's instructions. The products were analyzed using SDS-PAGE followed by autoradiography.
Transfections and luciferase assays
Plasmid DNAs were prepared using the endotoxin-free Maxi-prep kit (Qiagen, Valencia, CA) and transfected using LipofectAMINE 2000 reagent (Life Technologies) into Vero, MeWo, or SKNMC, or SH-SY-5Y cells cultured in 12-well plates to 70% confluence (Jambal et al., 2003) . In the first experiment, Vero, MeWo, or human neuroblastoma cells were transfected with 800 ng of a plasmid containing fireflyluciferase gene driven by the SVV ORF 21 promoter, together with varying amounts of recombinant clones containing SVV ORF 62 or 63 DNA. For each time point, the total quantity of DNA was brought to 1200 ng by addition of vector DNA or SVV ORF 63-containing plasmid. An internal control consisted of 50 ng of a plasmid containing Renilla luciferase. The total amount of DNA (including vector DNA, recombinant DNAs containing SVV ORFs 62, 63, and SVV ORF 21 promoter, and plasmid containing Renilla luciferase) in each transfection was 2050 ng. In the second experiment, cells were transfected with a mixture of recombinant clones containing SVV ORF 62 (50 ng) and varying amounts of SVV ORF 63 (0-1250 ng) and the plasmid containing the firefly-luciferase gene driven by the SVV ORF 21 promoter (700 ng). All transfections included 50 ng of recombinant plasmid containing Renilla luciferase to normalize for transfection efficiency. The total amount of DNA in each transfection was 1950 ng. In both experiments, cells at 24 h after transfection were washed in PBS, scraped, and lysed and assayed for luciferase using the dual luciferase assay kit (Promega). All results were relative to the activity found when vector DNA was substituted for the SVV ORF 62 plasmid. Statistical analysis was performed on the transfection results using one-way analysis of variance with Dunnett's multiple comparison test.
